CAPR — Capricor Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $541.73m
- $393.59m
- $22.27m
- 43
- 13
- 60
- 32
Annual income statement for Capricor Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.31 | 0.245 | 2.55 | 25.2 | 22.3 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 14 | 20.9 | 32.2 | 49.3 | 64.8 |
| Operating Profit | -13.7 | -20.6 | -29.7 | -24.1 | -42.6 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -13.7 | -20 | -29 | -22.3 | -40.5 |
| Net Income After Taxes | -13.7 | -20 | -29 | -22.3 | -40.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -13.7 | -20 | -29 | -22.3 | -40.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -13.7 | -20 | -29 | -22.3 | -40.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.659 | -0.66 | -0.876 | -0.135 | -0.491 |